"These striking new findings validate the combination of INX-315 with CDK4/6 inhibitors as a promising therapeutic strategy with potential application beyond patients with CDK2-addicted cancers ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...